Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Spectral AI Inc. (MDAI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MDAI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -67.17% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 30.39M USD | Price to earnings Ratio - | 1Y Target Price 5.12 |
Price to earnings Ratio - | 1Y Target Price 5.12 | ||
Volume (30-day avg) 414110 | Beta 0.42 | 52 Weeks Range 0.82 - 3.25 | Updated Date 04/2/2025 |
52 Weeks Range 0.82 - 3.25 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.63 |
Earnings Date
Report Date 2025-03-28 | When - | Estimate -0.14 | Actual -0.0659 |
Profitability
Profit Margin -51.77% | Operating Margin (TTM) -14.61% |
Management Effectiveness
Return on Assets (TTM) -36.11% | Return on Equity (TTM) -2308.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 34744327 | Price to Sales(TTM) 1.03 |
Enterprise Value 34744327 | Price to Sales(TTM) 1.03 | ||
Enterprise Value to Revenue 1.27 | Enterprise Value to EBITDA -3.41 | Shares Outstanding 25325300 | Shares Floating 15158225 |
Shares Outstanding 25325300 | Shares Floating 15158225 | ||
Percent Insiders 32.5 | Percent Institutions 13.36 |
Analyst Ratings
Rating 4.75 | Target Price 4.93 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Spectral AI Inc.
Company Overview
History and Background
Spectral AI, Inc. was founded to develop and commercialize its DeepViewu00ae System. The DeepView System is intended to be used to determine burn depth in burn injuries, and to differentiate between viable and non-viable tissue in the treatment of soft tissue injuries. Spectral AI, Inc. was incorporated on January 14, 2008.
Core Business Areas
- DeepViewu00ae System: The DeepViewu00ae System provides clinicians with an objective, spectral-based assessment of tissue viability, aiming to reduce the need for subjective clinical assessments and potentially improve treatment outcomes.
Leadership and Structure
Key leaders include Wensheng Fan, CEO; Peter M. Savas, Chief Commercial Officer; Kurt Midkiff, CFO. Structure consists of a board of directors and an executive management team overseeing various departments.
Top Products and Market Share
Key Offerings
- DeepViewu00ae System: The DeepViewu00ae System is Spectral AI's flagship product, intended for use in assessing burn depth and tissue viability. Market share data is not readily available, but they operate in a niche market with competitors like Novadaq (now Stryker) using fluorescence imaging and other technologies using laser Doppler imaging.
Market Dynamics
Industry Overview
The advanced wound care market, including burn and soft tissue injury assessment, is growing due to increasing incidence of burns, diabetes, and an aging population. Technologies focus on improving diagnostic accuracy and treatment efficiency.
Positioning
Spectral AI is positioning itself as a leader in spectral imaging for tissue assessment, differentiating its technology based on its ability to provide objective, quantifiable data to clinicians. Its competitive advantage lies in the unique spectral imaging technology that provides a non-invasive tissue assessment solution.
Total Addressable Market (TAM)
The TAM for burn and wound care is estimated to be in the billions globally. Spectral AI, with its DeepView system, aims to capture a significant portion of this market by offering improved diagnostic capabilities.
Upturn SWOT Analysis
Strengths
- Proprietary spectral imaging technology
- Potential for improved diagnostic accuracy
- Non-invasive assessment
- FDA clearance for DeepViewu00ae System
- Experienced leadership team
Weaknesses
- Limited commercialization experience
- Reliance on single product (DeepViewu00ae System)
- Small market capitalization, could affect fundraising
- High operating expenses
Opportunities
- Expanding applications beyond burns (e.g., diabetic ulcers)
- Partnerships with hospitals and burn centers
- International expansion
- Further development of AI-based diagnostic tools
- Securing additional funding for growth
Threats
- Competition from established players in wound care
- Regulatory hurdles for new applications
- Reimbursement challenges for new technologies
- Technological obsolescence
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- STRY
- LIVN
- BSX
Competitive Landscape
Spectral AI's advantage is its unique spectral imaging technology. Disadvantages include limited financial resources compared to larger competitors and a smaller sales and marketing footprint.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the early stage of commercialization. Revenue has increased recently with initial sales of the DeepViewu00ae System.
Future Projections: Future growth projections are dependent on the successful commercialization and adoption of the DeepViewu00ae System, as well as potential expansion into new markets and applications. Analyst estimates expect revenue growth to increase exponentially.
Recent Initiatives: Recent initiatives include obtaining FDA clearance for DeepViewu00ae, expanding the sales team, and forging partnerships with key hospitals and burn centers.
Summary
Spectral AI is an early-stage company with promising technology but faces significant execution risks. Its DeepView system has the potential to improve burn care and other tissue assessment applications. It's strengths lie in its unique technology, but it needs to strengthen its financial position, sales and marketing efforts, and market penetration. Spectral AI needs to be wary of the larger companies.
Similar Companies
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
LIVN
LivaNova PLC
LIVN
LivaNova PLC
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Press Releases
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investing in stocks involves risk, including the potential loss of principal.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Spectral AI Inc.
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2021-04-06 | Co-Founder, Chief Innovation Strategist & Senior Advisor to the CEO Mr. Wensheng Fan | ||
Sector Healthcare | Industry Medical Devices | Full time employees - | Website https://www.spectral-ai.com |
Full time employees - | Website https://www.spectral-ai.com | ||
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.